Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. (Q33350210)

26 July 2017

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. (English)

1 reference

ookinete surface protein P25

26 July 2017

phase I clinical trial

0 references

1 reference

GeneDB

ookinete surface protein P25, putative

11 September 2018

1 reference

25 September 2018

0 references

1 reference

1 reference

Siddhartha Mahanty

6

0 references

David L. Narum

David Narum

8

0 references

Michael P. Fay

Michael P Fay

7

0 references

Allan Saul

Allan Saul

19

0 references

Kazutoyo Miura

17

Kazutoyo Miura

1 reference

26 July 2017

18

Carole Long

1 reference

26 July 2017

2

Ruth D Ellis

1 reference

26 July 2017

20

Louis H Miller

1 reference

26 July 2017

21

Anna P Durbin

1 reference

26 July 2017

5

Elissa M Malkin

1 reference

26 July 2017

9

Kelly Rausch

1 reference

26 July 2017

11

Joan Aebig

1 reference

26 July 2017

3

Donna Shaffer

1 reference

26 July 2017

16

Daming Zhu

1 reference

26 July 2017

12

Andrew Orcutt

1 reference

26 July 2017

13

Olga Muratova

1 reference

26 July 2017

14

Guanhong Song

1 reference

26 July 2017

15

Lynn Lambert

1 reference

26 July 2017

Yimin Wu

1

1 reference

26 July 2017

Erica Fontes

4

1 reference

26 July 2017

Aaron P Miles

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 July 2008

1 reference

26 July 2017

1 reference

26 July 2017

3

1 reference

26 July 2017

e2636

1 reference

26 July 2017

7

1 reference

Creative Commons CC0 License

26 July 2017

start time

9 July 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

cites work

Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Human immunity and the design of multi-component, single target vaccines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Revisiting Freund's incomplete adjuvant for vaccines in the developing world

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Insecticide-treated bed nets and curtains for preventing malaria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Transmission-blocking vaccines.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Erythema nodosum following typhoid vaccination.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

The 230-kDa gamete surface protein of plasmodium falciparum is also a target for transmission-blocking antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Hepatitis B vaccine associated with erythema nodosum and polyarthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Efficacy model for mosquito stage transmission blocking vaccines for malaria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440546

Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization

31 October 2018

1 reference

12 December 2020

Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial

1 reference

12 December 2020

Erythema nodosum and Takayasu's arteritis after immunization with plasma derived hepatitis B vaccine

1 reference

12 December 2020

Erythema nodosum provoked by hepatitis B vaccine

1 reference

12 December 2020

Safety and immunogenicity of REMUNE in HIV-infected Thai subjects

1 reference

12 December 2020

Erythema nodosum after Recombivax HB hepatitis B vaccine

1 reference

12 December 2020

The use of oil adjuvants in therapeutic vaccines

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0002636

Identifiers

DOI

1 reference

26 July 2017

0 references

1 reference

26 July 2017

1 reference